This isn't all that exciting, but it's something...


Transition Therapeutics Commences Enrolment for Multiple Sclerosis Phase II Clinical Trial

Jan. 28 - Transition Therapeutics Inc., announced today that patient enrolment has commenced for a Phase II clinical trial of its Interferon Enhancing Therapy ("MS-I.E.T.") in patients with multiple sclerosis ("MS"). MS-I.E.T. combines interferon-(B) with Transition's enhancing agent, EMZ701, with the goal of improving outcomes in MS patients without adding toxicity.

"With a real medical need ...

Novartis impresses with 2005 product pipeline

January 12, 2005 - One drug that is expected to make waves in the long term is transplant drug FTY720. The treatment works by a unique mechanism of action, directing T-cells away from the graft.

Despite its long-term importance, in the short and medium term only modest sales are expected due to the need to build clinical trial data and to the conservative nature of transplantation physicians. Transplantation is ...

Serono and IVAX to Initiate Phase III Clinical Trial of Mylinax(R) in Multiple Sclerosis

January 11, 2005 - PRNewswire-FirstCall - Serono and IVAX Corporation announced today that they will initiate a Phase III study with Mylinax(R) (a proprietary oral formulation of cladribine) in the first quarter of 2005. This multi-center, multi-national study is designed to assess the effectiveness of Mylinax(R) in patients with relapsing forms of multiple sclerosis. Endpoints will include assessments of clinical relapses, ...

Antisense Therapeutics Limited and Isis Pharmaceuticals Initiate Phase 2a Trial of Antisense Drug for Multiple Sclerosis
Tuesday December 21, 7:55 am ET

PRNewswire-FirstCall - Antisense Therapeutics Limited and Isis Pharmaceuticals announced today the initiation of a Phase 2a clinical trial of ATL1102 in patients with multiple sclerosis (MS).

ATL1102 is a second-generation antisense inhibitor of an immune system protein called VLA-4 (alpha-4 integrin chain; CD49d). ATL1102 is designed to block the synthesis of VLA-4 which ...

Early days, but an interesting approach.

A USC-invented vaccine for multiple sclerosis (MS) is about to enter
Phase II clinical trials
http://www.usc.edu/hsc/info/pr/1vol5/526/ms.html

A USC-invented vaccine for multiple sclerosis (MS) is about to enter
Phase II clinical trials, backed by a combined $3.5 million in
funding-including a $1.1 million award from the National Multiple
Sclerosis Society that is one of its largest in recent memory, as well
as $2.4 million ...

Folks, ' myelinrepair.org ' May answer some of our questions. They have just posted some of their research findings on cell life cycle and myelin cycles, and possible preservation. A foundation of ONE of us, working to find a cure as quickly as possible. Take a look! HaGrtD ZZZZ

Dear all,

The following article was on the BBC's website today. While not directly related to MS there is some very familiar language - inflammation in the brain etc.

I hope it is of interest to those with a more scientific bent e.g. OddDuck.

Bromley

PS Given all her contributions, shouldn't we be paying OddDuck?



Brain inflammation link to autism

Autism is a mysterious condition
Scientists have produced compelling evidence that autism may in some ...

Another new one in the very early stages...


Drug may offer relief from Crohn's disease

From Associated Press - November 15, 2004

An experimental drug that selectively tamps down part of the immune system can offer dramatic relief to many victims of the painful bowel disorder Crohn's disease, and might also work against illnesses such as arthritis and multiple sclerosis, researchers have found.

Other drugs are already available against Crohn's, but their effectiveness is spotty. ...

This is still being tested on rats, but I like that it seems to enhance the replacement of myelin.



Thyroid Hormone May Help Repair MS Damage
Tue 9 November, 2004 20:19

NEW YORK (Reuters Health) - Treatment with thyroid hormone enhances the replacement of myelin -- the insulating sheath around brain neurons -- in rats with a chronic demyelinating disease, researchers report

Since loss of myelin is the underlying problem in multiple sclerosis (MS), the ...

This article talks about an early phase MS therapeutic I haven't heard of before, Tovaxin...


PharmaFrontiers Completes Acquisition of Multiple Sclerosis Cell Therapy Developer Opexa Pharmaceuticals Inc.

HOUSTON--(BUSINESS WIRE)--Nov. 8, 2004--Cell therapy developer PharmaFrontiers Corporation (OTCBB:PFTR) has closed its previously announced acquisition of Opexa Pharmaceuticals Inc., a Houston-based developer of cell-based therapeutics for autoimmune diseases, initially targeting multiple sclerosis (MS).

In the all-stock transaction, Opexa shareholders received 2.5 million shares, or approximately 25 percent of ...